JP2007504229A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2007504229A5 JP2007504229A5 JP2006525369A JP2006525369A JP2007504229A5 JP 2007504229 A5 JP2007504229 A5 JP 2007504229A5 JP 2006525369 A JP2006525369 A JP 2006525369A JP 2006525369 A JP2006525369 A JP 2006525369A JP 2007504229 A5 JP2007504229 A5 JP 2007504229A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- treating
- preventing
- alkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 20
- 125000000217 alkyl group Chemical group 0.000 claims 12
- 125000003118 aryl group Chemical group 0.000 claims 10
- 125000001072 heteroaryl group Chemical group 0.000 claims 9
- 125000000304 alkynyl group Chemical group 0.000 claims 8
- 150000001875 compounds Chemical class 0.000 claims 8
- 150000003839 salts Chemical class 0.000 claims 8
- 125000001424 substituent group Chemical group 0.000 claims 8
- 125000000753 cycloalkyl group Chemical group 0.000 claims 7
- 125000000623 heterocyclic group Chemical group 0.000 claims 7
- 229910052739 hydrogen Inorganic materials 0.000 claims 6
- 239000001257 hydrogen Substances 0.000 claims 6
- 208000019901 Anxiety disease Diseases 0.000 claims 5
- 125000003342 alkenyl group Chemical group 0.000 claims 5
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims 5
- 208000002193 Pain Diseases 0.000 claims 4
- 239000003937 drug carrier Substances 0.000 claims 4
- 125000006374 C2-C10 alkenyl group Chemical group 0.000 claims 3
- 125000004093 cyano group Chemical group *C#N 0.000 claims 3
- 208000019116 sleep disease Diseases 0.000 claims 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical group N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 2
- 208000020925 Bipolar disease Diseases 0.000 claims 2
- 208000017164 Chronobiology disease Diseases 0.000 claims 2
- 206010065390 Inflammatory pain Diseases 0.000 claims 2
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 claims 2
- 230000027288 circadian rhythm Effects 0.000 claims 2
- 208000010877 cognitive disease Diseases 0.000 claims 2
- 229910052736 halogen Inorganic materials 0.000 claims 2
- 150000002367 halogens Chemical class 0.000 claims 2
- 208000004296 neuralgia Diseases 0.000 claims 2
- 208000021722 neuropathic pain Diseases 0.000 claims 2
- 229910052760 oxygen Inorganic materials 0.000 claims 2
- 208000020685 sleep-wake disease Diseases 0.000 claims 2
- 208000011117 substance-related disease Diseases 0.000 claims 2
- 229910052717 sulfur Inorganic materials 0.000 claims 2
- 208000008811 Agoraphobia Diseases 0.000 claims 1
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 208000000044 Amnesia Diseases 0.000 claims 1
- 208000000094 Chronic Pain Diseases 0.000 claims 1
- 208000019888 Circadian rhythm sleep disease Diseases 0.000 claims 1
- 208000028698 Cognitive impairment Diseases 0.000 claims 1
- 206010012289 Dementia Diseases 0.000 claims 1
- 206010013654 Drug abuse Diseases 0.000 claims 1
- 208000030814 Eating disease Diseases 0.000 claims 1
- 208000019454 Feeding and Eating disease Diseases 0.000 claims 1
- 208000011688 Generalised anxiety disease Diseases 0.000 claims 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 1
- 208000001456 Jet Lag Syndrome Diseases 0.000 claims 1
- 208000026139 Memory disease Diseases 0.000 claims 1
- 241000208125 Nicotiana Species 0.000 claims 1
- 235000002637 Nicotiana tabacum Nutrition 0.000 claims 1
- 208000008589 Obesity Diseases 0.000 claims 1
- 206010033664 Panic attack Diseases 0.000 claims 1
- 208000018737 Parkinson disease Diseases 0.000 claims 1
- 206010034912 Phobia Diseases 0.000 claims 1
- 208000028017 Psychotic disease Diseases 0.000 claims 1
- 208000027520 Somatoform disease Diseases 0.000 claims 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims 1
- 208000031674 Traumatic Acute Stress disease Diseases 0.000 claims 1
- 208000005298 acute pain Diseases 0.000 claims 1
- 208000026345 acute stress disease Diseases 0.000 claims 1
- 125000003545 alkoxy group Chemical group 0.000 claims 1
- 230000036506 anxiety Effects 0.000 claims 1
- 125000004104 aryloxy group Chemical group 0.000 claims 1
- 125000004429 atom Chemical group 0.000 claims 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 1
- 229910052799 carbon Inorganic materials 0.000 claims 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 235000014632 disordered eating Nutrition 0.000 claims 1
- 206010013663 drug dependence Diseases 0.000 claims 1
- 208000029364 generalized anxiety disease Diseases 0.000 claims 1
- 208000014617 hemorrhoid Diseases 0.000 claims 1
- 125000005842 heteroatom Chemical group 0.000 claims 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 1
- 208000033915 jet lag type circadian rhythm sleep disease Diseases 0.000 claims 1
- 230000006984 memory degeneration Effects 0.000 claims 1
- 208000023060 memory loss Diseases 0.000 claims 1
- 229910052757 nitrogen Chemical group 0.000 claims 1
- 235000020824 obesity Nutrition 0.000 claims 1
- 239000001301 oxygen Substances 0.000 claims 1
- 208000027753 pain disease Diseases 0.000 claims 1
- 208000019906 panic disease Diseases 0.000 claims 1
- 230000002085 persistent effect Effects 0.000 claims 1
- 208000019899 phobic disease Diseases 0.000 claims 1
- 208000028173 post-traumatic stress disease Diseases 0.000 claims 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 1
- 201000000980 schizophrenia Diseases 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- 239000011593 sulfur Chemical group 0.000 claims 1
- 0 CCOc1c(Nc2cccc(C)n2)ncc(*)c1 Chemical compound CCOc1c(Nc2cccc(C)n2)ncc(*)c1 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US49962703P | 2003-09-02 | 2003-09-02 | |
| PCT/US2004/027916 WO2005021529A1 (en) | 2003-09-02 | 2004-08-27 | Bipyridyl amines and ethers as modulators of metabotropic glutamate receptor-5 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2007504229A JP2007504229A (ja) | 2007-03-01 |
| JP2007504229A5 true JP2007504229A5 (enExample) | 2007-07-05 |
Family
ID=34272848
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006525369A Withdrawn JP2007504229A (ja) | 2003-09-02 | 2004-08-27 | 代謝調節型グルタミン酸受容体−５のモジュレーターとしてのビピリジルアミン類およびエーテル類 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20070027321A1 (enExample) |
| EP (1) | EP1664018A1 (enExample) |
| JP (1) | JP2007504229A (enExample) |
| CN (1) | CN1845915A (enExample) |
| AU (1) | AU2004268112A1 (enExample) |
| CA (1) | CA2537141A1 (enExample) |
| WO (1) | WO2005021529A1 (enExample) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4286146B2 (ja) * | 2001-12-18 | 2009-06-24 | メルク エンド カムパニー インコーポレーテッド | メタボトロピックグルタミン酸受容体−５のヘテロアリール置換ピラゾール系調節剤 |
| EP1485093B1 (en) * | 2002-03-12 | 2010-11-03 | Merck Sharp & Dohme Corp. | Di-aryl substituted tetrazole modulators of metabotropic glutamate receptor-5 |
| JP2006522128A (ja) * | 2003-04-03 | 2006-09-28 | メルク エンド カムパニー インコーポレーテッド | 代謝調節型グルタミン酸受容体−５のモジュレーターとしての４環イミダゾール誘導体 |
| EP1613614A2 (en) * | 2003-04-03 | 2006-01-11 | Merck & Co., Inc. | Di-aryl substituted pyrazole modulators of metabotropic glutamate receptor-5 |
| US8735595B2 (en) * | 2006-02-15 | 2014-05-27 | Abbvie Inc. | Acetyl-CoA carboxylase (ACC) inhibitors and their use in diabetes, obesity and metabolic syndrome |
| PT2402319T (pt) * | 2006-03-31 | 2017-12-11 | Novartis Ag | Inibidores de dgat |
| CN101730684B (zh) * | 2007-06-18 | 2013-07-24 | 吉瑞工厂 | 磺酰基-喹啉衍生物 |
| EA019104B1 (ru) * | 2007-09-21 | 2014-01-30 | Эррей Биофарма Инк. | Активаторы глюкокиназы |
| KR20100090250A (ko) | 2007-10-09 | 2010-08-13 | 메르크 파텐트 게엠베하 | 글루코키나제 활성체로서 유용한 피리딘 유도체 |
| US7800382B2 (en) | 2007-12-19 | 2010-09-21 | AEHR Test Ststems | System for testing an integrated circuit of a device and its method of use |
| JPWO2009130900A1 (ja) * | 2008-04-24 | 2011-08-11 | 日本曹達株式会社 | オキシム誘導体、中間体化合物および植物病害防除剤 |
| CA2746307C (en) | 2008-12-17 | 2013-11-19 | Amgen Inc. | Aminopyridine and carboxypyridine compounds as phosphodiesterase 10 inhibitors |
| US8030957B2 (en) | 2009-03-25 | 2011-10-04 | Aehr Test Systems | System for testing an integrated circuit of a device and its method of use |
| KR20140051834A (ko) * | 2011-03-09 | 2014-05-02 | 다이이찌 산쿄 가부시키가이샤 | 디피리딜아민 유도체 |
| WO2012151137A1 (en) | 2011-05-04 | 2012-11-08 | Merck Sharp & Dohme Corp. | Amino-pyridine-containing spleen tyrosine kinase (syk) inhibitors |
| WO2013081094A1 (ja) * | 2011-11-30 | 2013-06-06 | 東レ株式会社 | イミダゾ［１，２－ａ］ピリジン誘導体及びその医薬用途 |
| JP6267193B2 (ja) * | 2012-05-22 | 2018-01-24 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | 置換ジピリジルアミン類及びそれらの使用 |
| JP2014196274A (ja) * | 2013-03-29 | 2014-10-16 | 三井化学株式会社 | 多環芳香族炭化水素の誘導体の製造方法 |
| KR102288542B1 (ko) * | 2014-12-24 | 2021-08-11 | 삼성에스디아이 주식회사 | 웨어러블 기기의 무선 충전 장치 및 시스템 |
| CA3058182A1 (en) | 2017-03-27 | 2018-10-04 | Cardurion Pharmaceuticals, Llc | Heterocyclic compound |
| WO2019126731A1 (en) * | 2017-12-22 | 2019-06-27 | Petra Pharma Corporation | Aminopyridine derivatives as phosphatidylinositol phosphate kinase inhibitors |
| JP7447098B2 (ja) | 2018-09-25 | 2024-03-11 | カーデュリオン・ファーマシューティカルズ・インコーポレイテッド | アミノピリミジン化合物 |
| TW202112767A (zh) | 2019-06-17 | 2021-04-01 | 美商佩特拉製藥公司 | 作為磷脂酸肌醇磷酸激酶抑制劑之胺基吡啶衍生物 |
| EP4007575B1 (en) * | 2019-11-05 | 2023-09-27 | Claes THULIN | 4-[5-[(rac)-1-[5-(3-chlorophenyl)-3-isoxazolyl]ethoxy]-4-methyl-4h-1,2,4-triazol-3-yl]pyridine for use in prevention and/or treatment of stress |
| WO2021143729A1 (zh) * | 2020-01-15 | 2021-07-22 | 中国科学院上海药物研究所 | 多靶点抑制作用化合物、组合物、功能分子及其应用 |
| JP7824282B2 (ja) | 2020-09-28 | 2026-03-04 | カーデュリオン・ファーマシューティカルズ・インコーポレイテッド | 縮合ヘテロアリール化合物およびＣａＭＫＩＩ阻害剤としてのその使用 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE422799B (sv) * | 1975-05-28 | 1982-03-29 | Merck & Co Inc | Analogiforfarande for framstellning av 1,3-dihydroimidazo (4,5-b)pyridin-2-oner |
| US5891601A (en) * | 1996-10-16 | 1999-04-06 | Sumitomo Chemical Company, Ltd. | Positive resist composition |
| US6180650B1 (en) * | 1999-04-23 | 2001-01-30 | Merck Frosst Canada & Co. | Heterosubstituted pyridine derivatives as PDE 4 inhibitors |
| US6660753B2 (en) * | 1999-08-19 | 2003-12-09 | Nps Pharmaceuticals, Inc. | Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists |
| ATE287888T1 (de) * | 2000-07-04 | 2005-02-15 | Neurosearch As | Aryl- und heteroaryldiazabicycloalkane, deren zubereitung und verwendung |
| CA2462289C (en) * | 2001-10-04 | 2010-02-23 | Nicholas D. Cosford | Heteroaryl substituted tetrazole modulators of metabotropic glutamate receptor-5 |
| AU2002365892A1 (en) * | 2001-11-30 | 2003-06-17 | Merck & Co., Inc. | Metabotropic glutamate receptor-5 modulators |
| JP4286146B2 (ja) * | 2001-12-18 | 2009-06-24 | メルク エンド カムパニー インコーポレーテッド | メタボトロピックグルタミン酸受容体−５のヘテロアリール置換ピラゾール系調節剤 |
| EP1458708B1 (en) * | 2001-12-18 | 2007-09-26 | Merck & Co., Inc. | Heteroaryl substituted triazole modulators of metabotropic glutamate receptor-5 |
| JP4357965B2 (ja) * | 2001-12-21 | 2009-11-04 | メルク エンド カムパニー インコーポレーテッド | メタボトロピックグルタミン酸受容体−５のヘテロアリール置換ピロールモジュレーター |
| EP1485093B1 (en) * | 2002-03-12 | 2010-11-03 | Merck Sharp & Dohme Corp. | Di-aryl substituted tetrazole modulators of metabotropic glutamate receptor-5 |
| JP2006522128A (ja) * | 2003-04-03 | 2006-09-28 | メルク エンド カムパニー インコーポレーテッド | 代謝調節型グルタミン酸受容体−５のモジュレーターとしての４環イミダゾール誘導体 |
| EP1613614A2 (en) * | 2003-04-03 | 2006-01-11 | Merck & Co., Inc. | Di-aryl substituted pyrazole modulators of metabotropic glutamate receptor-5 |
| CN100537564C (zh) * | 2003-04-04 | 2009-09-09 | 麦克公司 | 代谢型谷氨酸受体-5的二芳基取代三唑调节剂 |
| CA2425817A1 (en) * | 2003-04-17 | 2004-10-17 | Queen's University At Kingston | Organic luminescent compounds and methods of making and using same |
| US20060189661A1 (en) * | 2003-11-03 | 2006-08-24 | Wagenen Bradford V | Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists |
| EP1715867A4 (en) * | 2004-02-12 | 2009-04-15 | Merck & Co Inc | BIPYRIDYLAMIDE AS MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR-5 |
-
2004
- 2004-08-27 CN CNA2004800250675A patent/CN1845915A/zh active Pending
- 2004-08-27 CA CA002537141A patent/CA2537141A1/en not_active Abandoned
- 2004-08-27 WO PCT/US2004/027916 patent/WO2005021529A1/en not_active Ceased
- 2004-08-27 JP JP2006525369A patent/JP2007504229A/ja not_active Withdrawn
- 2004-08-27 EP EP04782403A patent/EP1664018A1/en not_active Withdrawn
- 2004-08-27 AU AU2004268112A patent/AU2004268112A1/en not_active Abandoned
- 2004-08-27 US US10/570,068 patent/US20070027321A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5442717B2 (ja) | 二置換フタラジンヘッジホッグ経路アンタゴニスト | |
| KR102093608B1 (ko) | 이미다조피리딘 화합물 | |
| JP4216196B2 (ja) | Ｎｐｙアンタゴニストとしてのキノリン誘導体 | |
| US8993594B2 (en) | Isoquinolin-1(2H)-one derivatives as PARP-1 inhibitors | |
| JP2007523152A5 (enExample) | ||
| JP3357677B2 (ja) | 療法、特に良性前立腺過形成の治療において有用なキノリンおよびキナゾリン化合物 | |
| JP6380777B2 (ja) | ＰＩ３Ｋ、ｍＴＯＲ阻害薬としての縮合キノリン化合物 | |
| JP2005518414A5 (enExample) | ||
| JP2006507355A5 (enExample) | ||
| JP2007511504A5 (enExample) | ||
| JP2008513516A5 (enExample) | ||
| JP2009536161A5 (enExample) | ||
| JPWO2000039116A1 (ja) | アミノピラゾール誘導体 | |
| WO2001062738A1 (en) | Novel imidazoline compounds | |
| KR102404865B1 (ko) | 항종양제 | |
| JP2010504908A5 (enExample) | ||
| JP2013509392A5 (enExample) | ||
| JP2004507527A5 (enExample) | ||
| IE67288B1 (en) | 1-indolyalkyl-4-(alkoxypyrimidinyl) piperazines | |
| JP2004532823A5 (enExample) | ||
| JP2008505107A5 (enExample) | ||
| JP2010506919A5 (enExample) | ||
| JP2005511594A5 (enExample) | ||
| JP2008525513A5 (enExample) | ||
| JPWO2009041559A1 (ja) | インダゾールアクリル酸アミド化合物 |